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Abstract
Background—In 2012, over 48,000 pertussis cases were reported in the United States. Many 
cases occurred in vaccinated persons, showing that pertussis vaccination does not prevent all 
pertussis cases. However, pertussis vaccination may have an impact on disease severity.
Methods—We analyzed data on probable and confirmed pertussis cases reported through 
Enhanced Pertussis Surveillance (Emerging Infections Program Network) between 2010 and 2012. 
Surveillance data were collected through physician and patient interview and vaccine registries. 
We assessed whether having received an age-appropriate number of pertussis vaccines (AAV) (for 
persons aged ≥3 months) was associated with reduced odds of post-tussive vomiting, a marker of 
more clinically significant illness, or of severe pertussis (seizure, encephalopathy, pneumonia, 
and/or hospitalization). Adjusted odds ratios (aOR) were calculated using multivariable logistic 
regression.
Results—Among 9,801 pertussis patients aged ≥3 months, 77.6% were AAV. AAV status was 
associated with a 60% reduction in odds of severe disease in children 7 months–6 years old in 
multivariable logistic regression and a 30% reduction in odds of post-tussive vomiting in persons 
aged 19 months–64 years.
Conclusions—Serious pertussis symptoms and complications are less common among AAV 
pertussis patients, demonstrating that the positive impact of pertussis vaccination extends beyond 
decreasing risk of disease.
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Background
Pertussis, or whooping cough, is a highly contagious respiratory illness caused by the 
bacterium Bordetella pertussis. Symptoms include paroxysmal cough, post-tussive vomiting, 
apnea, and the characteristic “whoop”, especially in children [1]. The illness has a broad 
clinical spectrum, ranging from a mild cough to a severe illness with complications that can 
include cracked ribs, pneumonia, or, especially in infants, death [2].
Whole-cell pertussis vaccines were introduced in the United States in the 1940s; they were 
replaced by acellular vaccines during the 1990s due to concerns about adverse reactions 
[3,4]. The current Advisory Committee on Immunization Practices (ACIP) pertussis vaccine 
recommendations include a 5-dose primary series with DTaP (diphtheria toxoid-, tetanus 
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toxoid-, and acellular pertussis-containing) vaccine for children 2 months through 6 years of 
age [5] and an adolescent booster dose of Tdap (tetanus toxoid, reduced diphtheria toxoid 
and reduced acellular pertussis) vaccine at 11 or 12 years of age [6]. Older adolescents and 
adults who have not previously received Tdap are also recommended to receive a single dose 
of Tdap [6]. In October 2012, ACIP recommended that women receive a dose of Tdap 
during each pregnancy to protect infants through maternal antibody transfer [7]. US DTaP 
coverage is high: between 2008 and 2012, 83–85% of children aged 19–35 months had 
received ≥4 doses of DTaP [8]. Meanwhile, Tdap coverage among adolescents has increased 
steadily since its licensure in 2005, and in 2012, 85% of adolescents aged 13–17 years had 
received Tdap [9]. Although Tdap coverage has also increased among adults ≥19 years of 
age, only 14% of adults had received one Tdap dose in 2012 [10].
Despite high vaccination coverage in children and adolescents, the incidence of pertussis in 
the United States has been increasing since the late 1980s, with large outbreaks of disease in 
2004–2005, 2010, and 2012. In 2012, 48,277 pertussis cases were reported in the United 
States, the largest number since 1955 [11]. Numerous studies have documented waning 
immunity following acellular pertussis vaccination [12–14, reviewed in 15]. This waning 
immunity is likely a major contributor to the resurgence in disease [16] and explains the 
large proportion of US pertussis cases occurring among fully vaccinated individuals [17].
An important question is whether pertussis vaccination protects against severe disease. 
Previous analyses have suggested that pertussis infection is less severe in immunized 
children [18–26]; however, most of these studies were conducted in primarily whole-cell 
primed populations and many had sample sizes too small to fully assess confounding 
variables such as age, which is highly associated with both vaccination status and severity of 
pertussis illness. An exception is a recent analysis by Barlow et al. which found that 
vaccinated children and adolescents in the Portland, Oregon metropolitan area, who had 
received primarily acellular vaccine, had decreased severity and duration of illness compared 
to unvaccinated peers [18]. However, it was not clear whether these findings could be 
extended to a broader population. In addition, there are few data on pertussis severity among 
Tdap-vaccinated adults.
Here we describe the impact of pertussis immunization on disease severity in a population 
that includes children and adolescents vaccinated primarily with acellular pertussis vaccines 
as well as adults eligible to receive Tdap. We use data collected through the multistate 
Emerging Infections Program Network’s Enhanced Pertussis Surveillance (EPS) system to 
assess whether pertussis patients with age-appropriate vaccination were less likely to report 
serious pertussis symptoms or complications compared with unvaccinated or 
undervaccinated cases.
Methods
The analysis included pertussis cases in persons aged ≥3 months reported through EPS with 
cough onset between January 1, 2010 and December 31, 2012 [27]. Cases were reported 
statewide from Connecticut, Minnesota, and New Mexico, and from selected counties in 
Colorado (five Denver counties), New York (15 Rochester and Albany counties), and 
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Oregon (three Portland counties). Cases were included if they met the Council of State and 
Territorial Epidemiologists’ 2010–2013 probable or confirmed case definitions [28]:
• Probable case: Cough illness lasting ≥2 weeks and at least one of the following 
symptoms: paroxysms, inspiratory whoop, or post-tussive vomiting
• Confirmed case: Probable case with positive PCR or epidemiologic link to a 
laboratory-confirmed case; OR cough of any duration with isolation of B. 
pertussis.1
Information on pertussis-containing vaccines that patients received was collected routinely 
by EPS surveillance staff. After report of a case, surveillance staff collected vaccination 
history using medical records, state immunization registries, patient shot cards, school 
vaccine records, or patient self-report if other sources were not available. Information on 
pertussis vaccines received ≥2 weeks prior to cough onset was used to classify pertussis 
patients as having received an age-appropriate number of pertussis vaccinations (AAV) or 
not (nAAV), consistent with ACIP guidelines (Table 1). For persons aged ≥7 years not 
previously vaccinated for pertussis, a single dose of Tdap is recommended [29–30]. Because 
of this recommendation and the high frequency of missing data on childhood vaccinations in 
older age groups, adolescents and adults aged ≥13 were considered AAV if they had 
received a single dose of Tdap, regardless of other vaccination history. Vaccinations received 
after cough onset or less than 2 weeks prior to cough onset were not counted for 
determination of AAV status, and patients were considered unvaccinated if they had only 
received pertussis vaccinations within 2 weeks prior to cough onset or after cough onset.
Post-tussive vomiting was used as a marker of more clinically significant pertussis illness. 
We defined “severe disease” as one or more of the following: hospitalization, seizure, 
encephalopathy, positive x-ray for pneumonia, or death. Patients were classified as having 
received antibiotic treatment if they received an antibiotic recommended for the treatment of 
pertussis during the course of their infection [31].
Data were analyzed in SAS 9.3 (Cary, NC). To assess effect modification and confounding 
by age, cases aged ≤19 years were stratified by patient age groups corresponding to the 
number of doses needed to be classified as AAV2. Adults were classified into two age 
groups: 20–64 years and ≥65 years. Odds ratios (OR) were calculated using bivariate logistic 
regression to compare clinical characteristics of patients who were AAV vs. nAAV for 
pertussis vaccination (ages ≥3 months). Association of vaccination status with other patient 
characteristics, including patient state of residence, sex, race, ethnicity, and timing of 
antibiotic treatment, was assessed to identify potential confounders.
For multivariable logistic regression, we created two models: one using AAV status to 
predict post-tussive vomiting and a second using AAV status to predict severe disease. In 
each model, we included all age groups with similar, statistically significant (p<0.05) 
1In outbreak settings, outbreak-associated cases with cough illness lasting at least 2 weeks could also be reported as confirmed cases
2Age groups: 3–4 months (1 dose required to be AAV); 5–6 months (2 doses); 7–18 months (3 doses); 19 months–6 years (4 doses); 
7–12 years (5 doses, or 4 with 4th dose received after the 4th birthday); and 13–19 years (6 doses, or 5 with 4th dose received after the 
4th birthday; or Tdap received).
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unadjusted ORs for the relationship between the relevant vaccination and clinical variables 
in the bivariate analysis. The models included all variables that were significant (p<0.05) in 
bivariate analysis as well as a continuous age variable.
For patients 3 months to 19 years of age, we also classified patients as having ever or never 
received a pertussis vaccination and repeated the bivariate and multivariate analyses using 
this variable instead of AAV status. We considered patients to have ever received a pertussis 
containing vaccine if they had documentation or self-report of pertussis vaccine receipt ≥2 
weeks prior to cough onset; or if they had received ≥3 diphtheria-, tetanus-, or pertussis-
containing vaccines of unknown type (i.e. not known whether the vaccines contained tetanus 
and/or diphtheria antigens only or also contained pertussis). Logistic regression was used to 
assess time since Tdap vaccination (in years) as a predictor of post-tussive vomiting or 
severe disease among adolescents and adults.
Results
A total of 9,801 cases in patients aged ≥3 months were included in the analysis; 7,733 
(78.9%) were under 20 years of age and 55.8% were aged 7–19 years (Table 2). Overall 
44.9% of patients reported post-tussive vomiting (Table 3). One or more of the 
complications classified as severe disease were identified in 3.2% of cases; the most 
common complications were positive x-ray for pneumonia (N=170, 1.8%) and 
hospitalization (N=156, 1.6%). No deaths were reported. Both post-tussive vomiting and 
severe disease were significantly more common among laboratory confirmed cases 
compared with non-laboratory confirmed cases (post-tussive vomiting: OR 1.15, 95% CI 
1.05–1.26, p = 0.0019; severe disease: OR 1.61, 95% CI 1.20–2.15, p = 0.0014). Of patients 
aged ≥3 months, 77.6% were AAV for pertussis vaccination. Over 99% of patients with 
known antibiotic treatment status received an antibiotic for pertussis but the timing of 
antibiotic treatment varied from <7 days to ≥21 days after cough onset.
In bivariate logistic regression including patients from all age groups, we found that AAV 
status was protective against both post-tussive vomiting and severe disease (Table 4). Odds 
of post-tussive vomiting were highest among patients 3 months to 6 years of age and tended 
to decrease with increasing age (Table 4). Odds of post-tussive vomiting were also higher 
among patients with longer delays between cough onset and treatment initiation. Post-
tussive vomiting was also associated with state of residence, race, and ethnicity, with 
increased odds of post-tussive vomiting among American Indian/Alaskan Native, African 
American, and Other race individuals and among Hispanic individuals compared with white 
and Non-Hispanic persons, respectively. Odds of severe disease were highest among those 
aged 3–6 months and decreased with age before increasing again in persons aged ≥20 years 
and reaching a second peak in those aged ≥65 years. Odds of severe disease were also 
associated with state of residence.
After stratifying by age, we found that being AAV for pertussis vaccination was protective 
against post-tussive vomiting only in the 19 month–6 year, 7–12 year, 13–19 year, and 20–
64 year age groups and was protective against severe disease in the 7–18 month and 19 
month–6 year age groups (Table 5). We also assessed the number of pertussis-containing 
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vaccines received and found reduced odds of post-tussive vomiting in individuals who 
received 5 doses (19 month–6 year and 7–12 year age groups) or 6 doses (13–19 year age 
group) compared to those who received just one fewer dose (Supplementary Table 1). A 
similar analysis could not be conducted for severe disease due to the small number of cases 
with severe disease. In addition to assessing AAV status in 13–19 year olds, a sub-analysis 
was performed including only individuals aged 16–19 years, who would have been expected 
to receive at least one dose of whole-cell pertussis vaccine if vaccinated according to ACIP 
guidelines. Findings in this age group were similar to those in the full 13–19 year old age 
category: AAV status was associated with reduced odds of post-tussive vomiting (OR 0.68, 
95% CI 0.47–0.97, p=0.04) but not with severe disease (OR 1.76, 95% CI 0.48–6.37, 
p=0.39).
Multivariable models were constructed using all variables that were significant in the 
bivariate analysis, including age, state, race, ethnicity, AAV status, and timing of antibiotic 
treatment. The magnitude of association between vaccination status and clinical outcomes 
were similar across age groups in which a significant association between vaccination status 
and clinical outcome was detected in the bivariate analysis. Therefore, for the multivariable 
model for post-tussive vomiting, we combined all age groups that were significant in the 
bivariate analysis (19 months–64 years of age) and used a continuous variable for age. AAV 
status was associated with an approximately 30% reduction in odds of post-tussive vomiting 
after adjustment for confounders (Table 6). A multivariable model was also constructed to 
predict severe disease in persons 7 months–6 years of age; in this model, AAV status 
remained associated with an approximately 60% decrease in odds of severe disease (Table 
6).
For patients aged 3 months to 19 years, we repeated the analyses after re-classifying patients 
as having ever or never received a pertussis vaccination. Overall, 91.9% of patients in this 
age group had received at least one pertussis-containing vaccine. Results were similar to the 
results for AAV status in both bivariate and multivariable analysis, with the exception that 
having ever been vaccinated for pertussis was not protective against post-tussive vomiting 
among persons aged 13–19 years (data not shown). A similar analysis was not attempted for 
older patients due to the high frequency of missing vaccination data for individuals aged ≥20 
years.
Finally, we assessed whether the odds of post-tussive vomiting or severe disease increased 
with time since last pertussis vaccination. Due to the strong association between the 
outcomes of interest and age in younger age groups and the high collinearity of age and time 
since vaccination, we restricted this analysis to time since Tdap vaccination among 
adolescents and adults aged ≥13 years. We found a marginally significant association with 
each additional year since Tdap vaccination associated with a 1.33-fold increased odds of 
severe disease (95% CI 1.00–1.76, p = 0.049) among adolescents aged 13–19 years; no 
association between time since Tdap receipt and post-tussive vomiting or severe disease was 
observed for any other age group (data not shown).
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Discussion
Although waning immunity from acellular pertussis vaccines has contributed to a resurgence 
of pertussis cases in fully-vaccinated individuals [12–15], our analysis provides reassurance 
that pertussis is less severe in fully vaccinated individuals compared to individuals who are 
not up-to-date for pertussis vaccines. Findings from our study are consistent with an analysis 
by Barlow et al., which demonstrated that pertussis patients aged 6 weeks to 18 years who 
had ever received pertussis vaccination were less likely to be hospitalized or to develop 
severe illness [18]. Importantly, and in contrast to prior studies that focused exclusively on 
children age 18 and under [18–26], our analysis also included adults. We found that the 
protective effect of pertussis vaccination against more serious disease extends to adults, 
demonstrating that, although acellular pertussis vaccines have a diminished duration of 
protection from infection compared with whole-cell vaccines, both the childhood and adult 
ACIP pertussis vaccine recommendations lead to a reduction in the clinical severity of 
pertussis across all age groups.
In our analysis, the majority of adults and adolescents aged ≥16 would likely have received 
one or more doses of whole-cell pertussis vaccine as children based on their age and the date 
of introduction of acellular vaccines [2,3]. There is substantial evidence showing that 
individuals who have received at least one whole-cell pertussis vaccine have slower waning 
of immunity than individuals who have received only acellular pertussis vaccines [15]. It 
will therefore be important to continue monitoring the impact of adult pertussis vaccination 
as individuals who have received exclusively acellular pertussis vaccines reach adulthood.
Pertussis illness is most serious in young infants, and the primary goal of the US pertussis 
vaccination program is to prevent serious illness and deaths in this vulnerable age group. 
Although our analysis did not show a protective effect of vaccination against severe disease 
in children under 7 months of age, our data included relatively few cases in this age group – 
especially among those not fully vaccinated – and therefore had limited power to detect such 
an effect. A previous analysis of pertussis severity in infants demonstrated that receipt of 
even one pertussis vaccine dose is protective against severe disease and death in infants [32], 
highlighting the importance of receiving DTaP promptly at 2 months of age according to 
ACIP guidelines [5]. CDC further recommends that all pregnant women receive Tdap during 
every pregnancy to prevent serious illness and death among infants too young to receive 
vaccines [7]. Because the recommendation for Tdap receipt during pregnancy was not 
implemented until 2013 [7], we could not assess the impact of Tdap vaccination during 
pregnancy in our analysis.
Although our findings suggest that pertussis vaccination is protective against severe pertussis 
illness, one alternate explanation for this finding is that people who have received pertussis 
vaccines may have different healthcare-seeking behaviors or different access to care than 
people who do not receive vaccines. An association between vaccination and care-seeking 
behavior has previously been described for several other vaccines [33–35]; meanwhile, 
reduced access to care has previously been reported to disproportionately affect African 
American, Hispanic, and American Indian/Alaskan Native populations in the United States 
[36,37]. For either or both of these reasons, vaccinated individuals may be more likely to 
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receive care rapidly upon becoming ill, thus receiving antibiotic treatment earlier and 
reducing illness severity. However, although vaccinated individuals in our analysis were 
more likely to have received antibiotic treatment earlier in the course of their illness (data 
not shown), vaccination, antibiotic treatment timing, race, and ethnicity all remained 
significant in multivariable analysis of factors associated with post-tussive vomiting. These 
findings affirm the importance of both vaccination and early antibiotic treatment in 
mitigating pertussis severity. The impact of access to care on pertussis vaccination and 
treatment remains an important area for further study.
The availability of EPS surveillance data was critical for this analysis, as EPS features 
improved data completeness and enhanced verification of vaccination status compared to 
pertussis data collected through the US National Notifiable Diseases Surveillance System 
[27]. Nevertheless, the use of surveillance data in this analysis presented several challenges. 
Surveillance data include only pertussis cases that meet the clinical case definition, and so 
mild pertussis cases that do not meet this definition could not be included in our analysis. 
Furthermore, as most sites did not capture data on the full duration of cough due to resource 
limitations, we were not able to assess whether pertussis vaccination might be associated 
with a shorter duration of cough in pertussis cases as was recently shown by Barlow et al. 
[18]. In addition, although EPS sites make extensive efforts to confirm patient vaccination 
status, some persons with incomplete vaccination histories may still have been misclassified 
as unvaccinated or having not received an age-appropriate number of vaccinations. It is also 
possible that some unvaccinated or under-vaccinated persons may have been misclassified as 
having received age-appropriate vaccination based on erroneous self-report. Non-systematic 
misclassification of vaccination status would most likely bias our estimates towards the null, 
resulting in an underestimate of the true impact of pertussis vaccination on serious pertussis 
symptoms and complications.
By demonstrating that vaccinated children and adults are more likely to have less severe 
pertussis disease, our analysis highlights a benefit of the US pertussis vaccination program 
that extends beyond decreasing risk of disease. The impact of pertussis vaccination on 
lessening disease severity is particularly important given the resurgence of pertussis that is 
being observed among vaccinated persons in the United States. Although currently available 
pertussis vaccines cannot prevent all cases of pertussis illness, adherence to ACIP pertussis 
vaccine recommendations for infants, children, and adults remain critical to reduce 
pertussis-associated morbidity and mortality.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Summary
Analysis of US surveillance data demonstrates that both severe and clinically-significant 
pertussis illness are less common among patients who have received age-appropriate 
vaccination for pertussis, demonstrating that the positive impact of pertussis vaccination 
extends beyond decreasing risk of disease.
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Table 1
Age-Appropriate Vaccination (AAV) Definitions
Category Yes No Unknown
Age 3 months–
12 years
• Patient received 
recommended 
number of pertussis 
vaccinations for age
• Patient reported not 
receiving any pertussis 
vaccinations and no 
documentation of 
vaccination was found
• Patient received at least 
one pertussis vaccine, but 
not the full number 
recommended for age
• Not known whether patient 
had ever received a 
pertussis-containing 
vaccine
• Patient received at least 
one pertussis vaccine, but 
number of pertussis 
vaccines received could 
not be verified (and more 
than one is recommended 
based on age)
Age ≥13 years • Patient received 
recommended 
number of pertussis 
vaccinations for age
• Patient received 1 or 
more doses of Tdap, 
regardless of other 
vaccination history
• Patient reported not 
receiving any pertussis 
vaccinations and no 
documentation of 
vaccination was found
• Patient received at least 
one pertussis vaccine, but 
not the full number 
recommended for age 
AND had not received 
Tdap
• Not known whether patient 
had ever received a 
pertussis-containing 
vaccine
• Patient received at least 
one pertussis vaccine, but 
neither Tdap receipt nor 
number of pertussis 
vaccines received could be 
verified
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Table 2
Demographic characteristics of pertussis case in patients aged 3 months and older (N = 9,801)
Characteristic N %
State of residence
 Colorado 1208 12.3
 Connecticut 224 2.3
 Minnesota 5773 58.9
 New Mexico 1097 11.2
 New York 637 6.5
 Oregon 862 8.8
Sex
 Male 4448 45.4
 Female 5323 54.3
 Unknown 30 0.3
Pregnancy at cough onset (females aged 15–44)
 Non-pregnant 1119 80.7
 Pregnant 41 3.0
 Unknown 227 16.4
Race
 White 8006 81.7
 American Indian and Alaskan Natives 113 1.2
 Asian/Pacific Islander 190 1.9
 African American 389 4.0
 Other 195 2.0
 Unknown 908 9.3
Ethnicity
 Non-Hispanic 7578 77.3
 Hispanic 1467 15.0
 Unknown 756 7.7
Age
 3–4 months 194 2.0
 5–6 months 115 1.2
 7–18 months 366 3.7
 19 months – 6 years 1596 16.3
 7–12 years 3378 34.5
 13–19 years 2084 21.3
 20–64 years 1902 19.4
 65+ years 166 1.7
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Table 3
Clinical characteristics and vaccination status of pertussis cases in patients aged 3 months and older (N = 
9,801).
Characteristic N with non-missing information % with characteristic
Laboratory confirmation
 Culture or PCR positive for B. pertussis 9801 72.6
Cardinal pertussis symptoms
 Paroxysmal cough 9764 96.4
 Whoop 9529 28.7
 Apnea 9563 24.8
 Post-tussive vomiting 9662 44.9
 Seizure 9665 0.2
 Encephalopathy 9635 0.1
 Positive x-ray for pneumonia 9535 1.8
 Hospitalization 9690 1.6
 Death 9792 0
 Severe disease1 9362 3.2
Vaccination status
 Age-appropriate vaccination 8170 77.6
Timing of antibiotic treatment after cough onset
 < 7 days
9222
20.2
 7–13 days 32.2
 14–20 days 23.2
 21+ days 23.8
 Never 0.7
1Severe disease defined as having one or more of: seizure, encephalopathy, positive x-ray for pneumonia, hospitalization, or death
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